CN103784244A - Intrauterine implant - Google Patents
Intrauterine implant Download PDFInfo
- Publication number
- CN103784244A CN103784244A CN201310003855.5A CN201310003855A CN103784244A CN 103784244 A CN103784244 A CN 103784244A CN 201310003855 A CN201310003855 A CN 201310003855A CN 103784244 A CN103784244 A CN 103784244A
- Authority
- CN
- China
- Prior art keywords
- pastille
- intrauterine
- support
- diaphragm
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
- A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
Landscapes
- Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The invention relates to the field of medical instruments for gynecology, in particular to an intrauterine implant. The intrauterine implant comprises a stent (1) and a drug-containing diaphragm (3) coating the stent (1). By the intrauterine implant, the problems of stimulation influence on a uterus due to implantation of a long-term intrauterine implant, low uterine mucosa recovery effect, whole body influences caused by oral administration of hormone drugs and the like are improved to a great degree, and effect and individuation degree during phased use are improved greatly.
Description
Technical field
The present invention relates to gynecological's medical instruments field, particularly, the present invention relates to a kind of intrauterine implant.
Background technology
Intrauterine device (Intrauterine device, IUD) early than 1909 for contraception, be a kind of contraceptive effect good, safe, easy to use, economical, act on reversible long-acting contraception method.World Health Organization (WHO) statistics in 2002 show that existing 1.56 hundred million women in the whole world use IUD, and wherein Asian countries's user occupies the majority, and it is global 2/3 that Chinese user almost accounts for, and long-term use certificate understands that its safety can trust.
The present invention, on the product and shape basis of intrauterine device, removes the medicine and the copper product that play birth control effect, continues to use its safe mounting system, increases with the membrane structure of estrogen and progestogen medicine, to treat and to prevent in uterine cavity and the adhesion of cervix uteri.
Intrauterine adhesion claims again Asherman syndrome, refers to that uterine cavity flesh wall and/or neck tube are adhered mutually due to after uterine cavity due to various factors or neck tube basal layer inner film injury.Metrosynizesis is common gynecological disease, and basal layer endometrium sustains damage, and can produce fibrous connective tissue and be connected between uterine cavity inwall, even causes the disappearance of uterine cavity normal configuration, intrauterine adhesion sealing to no longer include lacuna when serious.Metrosynizesis is relevant with uterine neck diseases, repeatedly artificial abortion (particularly induced abortion), postoperative short-term sexual life and the operation lack of standardization of performing the operation with uterus.
Hysteroscope is the goldstandard of current intrauterine adhesion diagnosis and the prefered method for the treatment of, but follow-uply prevents that again in adhesion treatment, still there is no effectively in uterine cavity, to play barrier action carries out adhesion obstruct and promote the effective ways that inner membrance is grown.Meanwhile, for the prevention of the postoperative adhesion again of conventional intrauterine surgical, there is no good way yet.Conventional Therapeutic Method has several as follows at present:
1. intrauterine device
Current most scholar is using the classical way that after intrauterine adhesion exclusion, uterine cavity placement of intrauterine devices is adhered as prevention of postoperative for 2～3 months again.But not good enough for being adhered again effect after prevention severe intrauterine adhesion operation in patients, can not effectively intercept uterus front and rear wall; And may cause excessive inflammatory reaction, and cause a large amount of inflammatory mediators and urge being adhered formation release of cytokines, accelerate the postoperative formation being adhered again.
2. balloon expandable method
Commonly use clinically at present Foley sacculus urinary catheter as utricule.But there is retrograde infection, service time is shorter, use is inconvenient, sacculus water-filling pressure is difficult for the problems such as Accurate Measurement.
3. biogum class
At present clinical is mainly the hyaluronic derivant-self-crosslinking of latest generation polysaccharide gel (auto-cross-linked polysaccharides gel, ACPgel) for preventing the postoperative biogum that is adhered again formation of intrauterine adhesion.Can rest on for a long time the wound surface surface being adhered after separation, avoid wound surface to be affixed, inflammation-inhibiting cell migration, restriction Fibrinogen diffusion, thus play prevention of postoperative and be adhered again the effect of formation.Though ACPgel degradation time has clear improvement compared with HA, but the longest is 72 hours, though the effect that has prevention to be adhered again at the commitment of wound healing, but the wound healing later stage is adhered in the slow process of formation again, the effect of ACPgel is obviously not as good as intrauterine device and Foley sacculus urinary catheter, therefore expect that retention time is longer, more the biogum class of degradation resistant occurs.
4. estrogen
After intrauterine adhesion exclusion routine give oral or injection estrogen and progestogen sequential artificial cycle 2～3 months or apply separately estrogenic measure prevention light-certainly, menstruation recovery and reproduction prognosis all obviously improve to be adhered in formation effect after moderate intrauterine adhesion patient is adhered exclusion again.But severe intrauterine adhesion patient effect is pessimistic, the postoperative rate that is adhered again can reach more than 50%.Suggest severe intrauterine adhesion patient inner membrance basal layer destroys serious, in the situation of estrogen deficiency reaction, emphasizes simply whether high estrogen level can cause some short factor level that is adhered to rise, and increases the weight of to be adhered and the generation of intimal fibrosis again.In addition, can the estrogen through liver metabolism cannot be determined the bioavailability of remaining inner membrance effective stimulus, and oral administration can produce stimulation to whole body target organ, can aggravate the stimulation of endometriosis focus and breast tumor cell, be unfavorable for the fertility expection that patient is final.Therefore the effect that, estrogen is adhered in formation after severe intrauterine adhesion patient is adhered exclusion again needs further to be inquired into.Separately, a large-scale Denmark comparative study shows, uses the women of the oral contraceptive that contains a small amount of or minute quantity estradiol, and the relative risk that thrombotic apoplexy and myocardial infarction (MI) occur is 1 ~ 2 times of user not.
5. Fiber-hysteroscope is detected and blunt separation art
Intrauterine adhesion patient from postoperative 2 weeks, every within 1～3 week, carry out primary fiber hysteroscope detect with mirror under the newborn loose band blunt separation art that is adhered, what be adhered with prevention of postoperative densification forms again.Not there is not problems such as " intrauterine device bring out chronic inflammatory disease, and Foley sacculus urinary catheter causes infecting and incompetence,cervical " in the method, but still does not solve the problem of prevention and daily obstruct adhesion, and patient compliance is poor.
There are two main problems in above-mentioned these methods: 1, the impact of systemic administration.2, additive method is in operational low effect, inconvenience and risk.Can be found out by above analysis, keep the screen effect of uterine cavity implant and pass through to increase medicine local sustained release to eliminate hormone medicine systemic administration disadvantage, and by controlling the indwelling time of implant and discharging medicament categories, realization has stage chemotherapy journey arrangement, can realize the good result of the treatment of uterine cavity implant and prevention metrosynizesis.
Using this kind of uterine cavity implant product as medical apparatus and instruments, the application for the treatment of and prevention metrosynizesis does not also have report.
Summary of the invention
The object of the invention is to, a kind of uterine cavity implant that contains estrogen and/or progestogen, can intercept endometrium contact is provided, overcome on the one hand the side effect causing thus in whole body administration; On the other hand, strengthened barrier action and interim targetedly, the result of use of targeting medication.
For achieving the above object, intrauterine implant of the present invention, comprises support 1 and is coated on the pastille diaphragm 3 on support 1.
According to intrauterine implant of the present invention, described pastille diaphragm 3 is coated on support 1 and forms membrane layer.Further, described pastille diaphragm 3 can also divide some sections to be coated on and on support 1, to form membrane layer spaced apart.
According to intrauterine implant of the present invention, preferably, on the three-dimensional region of outline that described pastille diaphragm 3 integral coating form in support 1, form membrane body.
According to intrauterine implant of the present invention, further, described support 1 can be T shape, and the coated delta-shaped region forming with 1 liang of arm end points of support and vertical shaft bottom end points that is filled in of pastille diaphragm 3 forms membrane body.
Or described support 1 can be γ shape, the coated delta-shaped region forming with 1 liang of arm end points of support and bottom end points that is filled in of pastille diaphragm 3 forms membrane body.
Described support 1 shape can also be the distortion of above-mentioned T shape or γ shape, for example, each shape shown in the T-shaped or Fig. 6 of ring-type shown in Fig. 1, includes but not limited to γ shape, the fork-shaped etc. of the straight and sealing of V font, both arms that ring-type Y-shaped, Y-shaped, both arms are ring-type.
When above-mentioned support 1 is T shape, when γ shape or both distortion, described delta-shaped region forms membrane body, is not limited to regular triangle, also comprises the shape of irregular entirety structure triangular in shape, as triangle both sides are concavo-convex staggered structure.Particularly, for example both sides can be dentation, and described profile of tooth can be preferably trapezoidal or circular arc (as shown in figure 10).
Above-mentioned support 1 can also be annular, and pastille diaphragm 3 is coated and is filled in whole annular region.
Described support 1 is when annular, as shown in Figure 5, can also but be not limited to petal or butterfly that the Pear-Shaped of biarc connecting composition, four circular arcs form, fan-shaped etc., can also as required, difform supporter be set in annulus.Can also be as required, by pastille diaphragm 3 hollow outs (as shown in figure 11) in annulus.
According to intrauterine implant of the present invention, described pastille diaphragm 3 contained drugs are estrogen, progestogen or both mixture, and preferably, the outer medicine of pastille diaphragm 3 is estrogen, and interior nuclear pharmaceuticals is estrogen, both mixture of progestogen.
According to intrauterine implant of the present invention, the nearly cervix uteri end of described intrauterine implant is provided with pastille caudal vertebra 4, and described pastille caudal vertebra 4 contained drugs are estrogen, progestogen or both mixture.
According to intrauterine implant of the present invention, while forming membrane body on the three-dimensional region of outline forming in support 1 in above-mentioned pastille diaphragm 3 integral coating, can also on support 1, be provided with some pastille inclusion enclaves 2, described pastille inclusion enclave 2 thickness are higher than pastille diaphragm 3.These pastille inclusion enclave 2 contained drugs are estrogen, progestogen or both mixture, and the outer medicine of described pastille diaphragm 3 is estrogen, and interior nuclear pharmaceuticals is estrogen, both mixture of progestogen.
According to intrauterine implant of the present invention, the nearly cervix uteri end of described intrauterine implant can also be provided with pastille caudal vertebra 4, and described pastille caudal vertebra 4 contained drugs are estrogen, progestogen or both mixture.Described pastille caudal vertebra 4, rests in cervix uteri, plays the effect that prevents cervical adhesion, and increases the convenience of placing and taking out intrauterine implant.
According to intrauterine implant of the present invention, the nearly cervix uteri end of above-mentioned all types of implants can also be provided with tailfiber 5, the implant of conveniently taking, and described tailfiber 5 is medical polyester nylon wire.
According to intrauterine implant of the present invention, described support is medical corrosion-resistant metal materials support.Described pastille diaphragm, the material of pastille inclusion enclave and pastille caudal vertebra can be that medical anti-adhesive material is (such as silicone rubber, politef, ethyl cellulose nylon, medical natural polymer is (as osseocolla, gelatin, sodium alginate, agar, medical chitose (Medical Chitosan chitosan), hyaluronic acid and derivant thereof etc.), medical semisynthetic macromolecule (as cellulose derivative etc.), medical synthetic macromolecule is (as polydextrose acid, polylactic acid, polyglycolic acid, polyester, polydimethylsiloxane (PDMS) material) etc., wherein, being preferably silastic material makes.The diaphragm of making can folding and unfolding launches, and above-mentioned each parts contained drug is estrogen and/or progestogen, in uterine cavity slow release topical, prevent the general action of hormone medicine, the barrier action of performance medical grade silicon rubber material.
The present invention relates to a kind of uterine cavity implant containing estrogen and/or progestogen, improved significantly the stimulus effects implanting long-term uterine cavity implant uterus is caused, to Uterine mucosa repair effect the problem such as lower and drug-induced systemic effects of oral hormone class, and greatly improved effect and the personalized degree while use stage by stage.
Intrauterine implant of the present invention, described pastille diaphragm 3 can also be replaced by pastille diaphragm 7 not, i.e. and intrauterine implant of the present invention comprises support 1 and is coated on the not pastille diaphragm 7 on support 1.
According to intrauterine implant of the present invention, preferably, on the three-dimensional region of outline that described not pastille diaphragm 7 integral coating form in support 1, form membrane body.
According to intrauterine implant of the present invention, further, described support 1 can be T shape, and the coated delta-shaped region forming with 1 liang of arm end points of support and vertical shaft bottom end points that is filled in of pastille diaphragm 7 does not form membrane body.
Or described support 1 can be γ shape, the coated delta-shaped region forming with 1 liang of arm end points of support and bottom end points that is filled in of pastille diaphragm 7 does not form membrane body.
Described support 1 shape can also be the distortion of above-mentioned T shape or γ shape, for example, each shape shown in the T-shaped or Fig. 6 of ring-type as shown in Figure 1, includes but not limited to γ shape, the fork-shaped etc. of the straight and sealing of V font, both arms that ring-type Y-shaped, Y-shaped, both arms are ring-type.Wherein, the pastille inclusion enclave 2 of above-mentioned each figure, pastille diaphragm 3 and pastille caudal vertebra 4 by pastille inclusion enclave 6 not, not pastille diaphragm 7 and not pastille caudal vertebra 8 replace.
When above-mentioned support 1 is T shape, when γ shape or both distortion, described delta-shaped region forms membrane body, is not limited to regular triangle, also comprises the shape of irregular entirety structure triangular in shape, as triangle both sides are concavo-convex staggered structure.Particularly, for example both sides can be dentation, and described profile of tooth can be preferably trapezoidal or circular arc (as shown in figure 10, each pastille part all not pastille).
Above-mentioned support 1 can also be annular, and pastille diaphragm 7 is not coated and is filled in whole annular region.
Described support 1 is when annular, as shown in Figure 5, can also but be not limited to petal or butterfly that the Pear-Shaped of biarc connecting composition, four circular arcs form, fan-shaped etc., can also as required, difform supporter be set in annulus.Can also be as required, by not pastille diaphragm 7 hollow outs in annulus (as shown in figure 11, pastille part all not pastille).
According to intrauterine implant of the present invention, while forming membrane body on the three-dimensional region of outline forming in support 1 in above-mentioned not pastille diaphragm 7 integral coating, can also on support 1, be provided with some not pastille inclusion enclaves 6, described not pastille inclusion enclave 6 thickness are higher than pastille diaphragm 7 not.
According to intrauterine implant of the present invention, the nearly cervix uteri end of described intrauterine implant can also be provided with not pastille caudal vertebra 8, rests in cervix uteri, plays the effect that prevents cervical adhesion, and increases the convenience of placing and taking out intrauterine implant.Tailfiber 5 can also be set conveniently takes simultaneously.
Above-mentioned not pastille inclusion enclave 6 of the present invention, not pastille diaphragm 7 and the material of pastille caudal vertebra 8 not, identical with pastille caudal vertebra 4 with pastille inclusion enclave 2, pastille diaphragm 3, be only not contain any medicine.
The difference of not pastille intrauterine implant of the present invention and pastille intrauterine implant is, pastille inclusion enclave 2 is replaced by pastille inclusion enclave 6 not, and pastille diaphragm 3 is replaced by pastille diaphragm 7 not, and pastille caudal vertebra 4 is replaced by pastille caudal vertebra 8 not.
Do not contain the uterine cavity implant of medicine, except the physical barriers effect that has pastille uterine cavity implant to play, advantage easy to use, owing to not containing medicine, can on existing doctors experience medication basis, carry out external drug treatment by the person's of being combined with practical situation, and dosage and operational phase are carried out to personalization adjustment; Still can reach the repairing accelerant effect to Uterine mucosa adhesion.
To sum up, the invention has the advantages that: 1, have physical barriers effect, be convenient to treat in uterine cavity, the adhesion of cervix uteri; 2, due to containing estrogen and/or progestogen, there is the impact of accelerating rehabilitation for endometrium; Reduce the side reaction of systemic administration; 3, can be flexibly according to the occupation mode of the state of an illness and progress adjustment medicine containing the uterine cavity implant of medicine; 4,, owing to including medicine components difference, can be prepared as respectively the several types that only contains estrogen, contains estrogen and progestogen mixture, only contains progestogen; Can be in the cycle of every 30 days, the situation of repairing according to endometrium, selects different use orders, collocation order, can accomplish personalized treatment; 5, for conventional intrauterine operation, more convenient as preventative placement, the generation that can lower greatly metrosynizesis situation.
Accompanying drawing explanation
Fig. 1 intrauterine implant structure of the present invention schematic diagram (T annular).
Fig. 2 intrauterine implant structure of the present invention schematic diagram (T shape).
Fig. 3 intrauterine implant structure of the present invention schematic diagram (γ shape).
Fig. 4 intrauterine implant structure of the present invention schematic diagram (annular).
The schematic diagram of Fig. 5 intrauterine implant of the present invention annular related variation.
The schematic diagram of Fig. 6 intrauterine implant of the present invention T shape or γ shape related variation.
Fig. 7 intrauterine implant of the present invention is placed taking-up instrument.
Fig. 8 intrauterine implant structure of the present invention schematic diagram (T shape membrane body form)
Fig. 9 intrauterine implant structure of the present invention schematic diagram (T shape segmentation membrane body form)
Figure 10 intrauterine implant structure of the present invention schematic diagram (T shape dentation membrane body form)
Figure 11 intrauterine implant structure of the present invention schematic diagram (annular hollow out membrane body form)
Figure 12 intrauterine implant structure of the present invention schematic diagram (not pastille)
Accompanying drawing mark
1, support 2, pastille inclusion enclave 3, pastille diaphragm
4, pastille caudal vertebra 5, tailfiber 6, pastille inclusion enclave not
7, not pastille diaphragm 8, pastille caudal vertebra not
The specific embodiment
In order to understand better technical scheme of the present invention, below in conjunction with accompanying drawing, implementation step of the present invention is further described.
Intrauterine implant of the present invention, comprises support 1 and is coated on the pastille diaphragm 3 on support 1.
According to intrauterine implant of the present invention, as shown in Figure 8, described pastille diaphragm 3 is coated on support 1 and forms membrane layer.Further, as shown in Figure 9, described pastille diaphragm 3 can also divide some sections to be coated on and on support 1, to form membrane layer spaced apart.
According to intrauterine implant of the present invention, preferably, on the three-dimensional region of outline that described pastille diaphragm 3 integral coating form in support 1, form membrane body.
As illustrated in fig. 1 and 2, intrauterine implant of the present invention, described support 1 can be T shape, or according to the ring-type T shape of T deformation, the coated delta-shaped region forming with 1 liang of arm end points of support and vertical shaft bottom end points that is filled in of pastille diaphragm 3 forms membrane body.
As shown in Figure 3, intrauterine implant of the present invention, described support 3 can be γ shape, is provided with pastille inclusion enclave 2 at support two arms and ring bodies both sides, pastille diaphragm 3 parcels are filled in the Delta Region forming with support two arm end points and ring bodies lower extreme point.Described support shape can also be the distortion of above-mentioned T shape, T annular or γ shape, as shown in Figure 6, includes but not limited to γ shape, the fork-shaped etc. of the straight and sealing of V font, both arms that Y word annular, Y-shaped, both arms are ring-type.The implant bottom of above-mentioned each shape is provided with pastille caudal vertebra 4.Described pastille caudal vertebra 4 preferred materials are silica gel, rest in cervix uteri, play the effect that prevents cervical adhesion, and increase the convenience of placing and taking out intrauterine implant.
As shown in Figure 4, according to intrauterine implant of the present invention, it can also be annular, pastille diaphragm 3 is coated and is filled in whole annular region, as shown in Figure 5, described ring support, can also but be not limited to the petal or butterfly, fan-shaped etc. of the Pear-Shaped of biarc connecting composition, four circular arc compositions, can also as required, difform supporter be set in annulus.
The nearly cervix uteri end of above-mentioned each intrauterine implant also can be provided with pastille caudal vertebra 4.Described pastille caudal vertebra 4 contained drugs are estrogen, progestogen or both mixture.
Above-mentioned pastille diaphragm 3 contained drugs are estrogen, progestogen or both mixture.Particularly preferably, preparing in pastille diaphragm 3 processes, designing peripheral medicine is estrogen, and interior nuclear pharmaceuticals is estrogen, both mixture of progestogen.
While forming membrane body on the three-dimensional region of outline forming in support 1 in above-mentioned pastille diaphragm 3 integral coating, can also on support 1, be provided with some pastille inclusion enclaves 2, these pastille inclusion enclave 2 contained drugs are estrogen, progestogen or both mixture, and the outer medicine of described pastille diaphragm 3 is estrogen, interior nuclear pharmaceuticals is estrogen, both mixture of progestogen.
Intrauterine implant of the present invention is provided with tailfiber 5 at nearly cervix uteri end, can conveniently take, and described tailfiber 5 is medical polyester nylon wire.
Intrauterine implant of the present invention, specifically apply and operate as follows:
According to intrauterine implant of the present invention, in the time making pastille inclusion enclave, pastille diaphragm or pastille caudal vertebra, can be as required, after described estrogen, progestogen or the two mixture are mixed homogeneously with raw material (medical anti-adhesive material), molding, fill with mould, make corresponding pastille inclusion enclave, pastille diaphragm or pastille caudal vertebra.
The medication amount of putting into is added as basis take general knowledge known in this field, and preferably, each medicine requires the concentration discharging to see the following form 1 every day.
Table 1 medicine burst size every day
| Medicine | Require burst size every day |
| Estradiol | 30 mg/day and following |
| Natural progesterone | 40 micro-grams/day and following |
| Levonorgestrel | 20 micro-grams/day and following |
1, according to metrosynizesis and loosen postoperative situation, select the intrauterine implant that only containing estrogen, only contains progestogen or contain estrogen and progestogen mixture, generally only contain estrogenic type in just postoperative selection, use 30 days, then check, optionally have or not improvement and doctor's judgement, then select an intrauterine implant that only contains estrogen or only contain progestogen or contain estrogen and progestogen mixture.
2, according to doctor's judgement, select suitable uterine cavity implant take 30 days as one treatment cycle, can end in advance and change the intrauterine implant of variety classes (different pharmaceutical).
3,, according to doctor's judgement, can select one or more treatment cycle, to reach treatment and preventive effect.
4, laying method as IUD laying method, but will be by tailfiber 5 from intracavity extends to cervix uteri mouth.Place taking-up instrument as shown in Figure 7.
Intrauterine implant of the present invention, described pastille inclusion enclave 2, pastille diaphragm 3 and pastille caudal vertebra 4 can be respectively by pastille inclusion enclave 6 not, pastille diaphragm 7 is not replaced with pastille caudal vertebra 8 not, makes intrauterine implant entirety of the present invention containing medicine.Wherein an example as shown in figure 12.
The concrete application of intrauterine implant and the operation of not pastille of the present invention are as follows:
According to intrauterine implant of the present invention, in the time making, directly use raw material (medical anti-adhesive material), molding, filling mould, makes accordingly not pastille inclusion enclave, not pastille diaphragm or pastille caudal vertebra not.
1, according to metrosynizesis and loosen postoperative situation, select this intrauterine implant, use 30 days, then check, optionally has or not improvement and doctor's judgement, then selects new this intrauterine implant.At therapeutic process simultaneously, doctor should assist with external drug (oral or external) to reach therapeutic effect, and the medication amount that use is take general knowledge known in this field as basis.
2, according to doctor's judgement, select suitable uterine cavity implant take 30 days as one treatment cycle, can end in advance and change the intrauterine implant of variety classes (different pharmaceutical).
3,, according to doctor's judgement, can select one or more treatment cycle, to reach treatment and preventive effect.
4, laying method as IUD laying method, but will be by tailfiber 5 from intracavity extends to cervix uteri mouth.Place taking-up instrument as shown in Figure 7.
It should be noted last that, above embodiment is only unrestricted in order to technical scheme of the present invention to be described.Although the present invention is had been described in detail with reference to embodiment, those of ordinary skill in the art is to be understood that, technical scheme of the present invention is modified or is equal to replacement, do not depart from the spirit and scope of technical solution of the present invention, it all should be encompassed in the middle of claim scope of the present invention.
Claims (18)
1. an intrauterine implant, is characterized in that, described intrauterine implant comprises support (1) and is coated on the pastille diaphragm (3) on support (1).
2. intrauterine implant according to claim 1, is characterized in that, described pastille diaphragm (3) is coated on the upper membrane layer that forms of support (1).
3. intrauterine implant according to claim 1, is characterized in that, described pastille diaphragm (3) divides some sections to be coated on the upper formation of support (1) membrane layer spaced apart.
4. intrauterine implant according to claim 1, is characterized in that, on the three-dimensional region of outline that described pastille diaphragm (3) integral coating forms in support (1), forms membrane body.
5. intrauterine implant according to claim 4, is characterized in that, described support (1) is T shape, and the coated delta-shaped region forming with support (1) two arm end points and vertical shaft bottom end points that is filled in of pastille diaphragm (3) forms membrane body.
6. intrauterine implant according to claim 4, is characterized in that, described support (1) is γ shape, and the coated delta-shaped region forming with support (1) two arm end points and bottom end points that is filled in of pastille diaphragm (3) forms membrane body.
7. intrauterine implant according to claim 1, is characterized in that, described support (1) is annular, and pastille diaphragm (3) is coated and is filled in whole annular region.
8. according to the intrauterine implant described in claim 1-7, it is characterized in that, described pastille diaphragm (3) contained drug is estrogen, progestogen or both mixture.
9. according to the intrauterine implant described in claim 1-7, it is characterized in that, the nearly cervix uteri end of described intrauterine implant is provided with pastille caudal vertebra (4), and described pastille caudal vertebra (4) contained drug is estrogen, progestogen or both mixture.
10. according to the intrauterine implant described in claim 4-7, it is characterized in that, on described support (1), be also provided with some pastille inclusion enclaves (2), this pastille inclusion enclave (2) contained drug is estrogen, progestogen or both mixture, the outer medicine of described pastille diaphragm (3) is estrogen, and interior nuclear pharmaceuticals is estrogen, both mixture of progestogen.
11. intrauterine implants according to claim 10, is characterized in that, the nearly cervix uteri end of described intrauterine implant is provided with pastille caudal vertebra (4), and described pastille caudal vertebra (4) contained drug is estrogen, progestogen or both mixture.
12. 1 kinds of intrauterine implants, is characterized in that, described intrauterine implant comprises support (1) and is coated on the not pastille diaphragm (7) on support (1).
13. intrauterine implants according to claim 12, is characterized in that, on the three-dimensional region of outline that described not pastille diaphragm (7) integral coating forms in support (1), form membrane body.
14. intrauterine implants according to claim 13, is characterized in that, described support (1) is T shape, and the coated delta-shaped region forming with support (1) two arm end points and vertical shaft bottom end points that is filled in of pastille diaphragm (7) does not form membrane body.
15. intrauterine implants according to claim 13, is characterized in that, described support (1) is γ shape, and the coated delta-shaped region forming with support (1) two arm end points and bottom end points that is filled in of pastille diaphragm (7) does not form membrane body.
16. intrauterine implants according to claim 12, is characterized in that, described support (1) is annular, and pastille diaphragm (7) is not coated and is filled in whole annular region.
17. according to the intrauterine implant described in claim 12-16, it is characterized in that, is also provided with some not pastille inclusion enclaves (6) on described support (1).
18. according to the intrauterine implant described in claim 12-16, it is characterized in that, the nearly cervix uteri end of described intrauterine implant is provided with not pastille caudal vertebra (8).
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310003855.5A CN103784244B (en) | 2012-10-30 | 2013-01-06 | A kind of intrauterine implant |
| PCT/CN2013/001654 WO2014106315A1 (en) | 2013-01-06 | 2013-12-30 | Intrauterine implant |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210424513 | 2012-10-30 | ||
| CN201210424513.6 | 2012-10-30 | ||
| CN2012104245136 | 2012-10-30 | ||
| CN201310003855.5A CN103784244B (en) | 2012-10-30 | 2013-01-06 | A kind of intrauterine implant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103784244A true CN103784244A (en) | 2014-05-14 |
| CN103784244B CN103784244B (en) | 2016-03-23 |
Family
ID=51063017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310003855.5A Active CN103784244B (en) | 2012-10-30 | 2013-01-06 | A kind of intrauterine implant |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103784244B (en) |
| WO (1) | WO2014106315A1 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998343A (en) * | 2015-07-24 | 2015-10-28 | 严聪颖 | Medicine-prefilled and sustained-release apparatus for uterus uses and implantation method |
| CN105078642A (en) * | 2014-05-14 | 2015-11-25 | 饶永 | Implant for uteruses |
| CN105903092A (en) * | 2016-06-23 | 2016-08-31 | 刘芸 | Uterus implant and implanting system for same |
| CN105982779A (en) * | 2015-02-10 | 2016-10-05 | 刘雯倩 | Contraceptive ring |
| CN106573133A (en) * | 2014-08-19 | 2017-04-19 | 加利福尼亚大学董事会 | Implants for localized drug delivery and methods of use thereof |
| CN107951550A (en) * | 2017-12-14 | 2018-04-24 | 易浦润（上海）生物技术有限公司 | A kind of degradable inner membrane of uterine cavity implant system |
| CN108852569A (en) * | 2018-05-21 | 2018-11-23 | 柏为（武汉）医疗科技股份有限公司 | A kind of degradable support diaphragm apparatus for preventing and treating Asherman's syndrom |
| CN109602535A (en) * | 2019-02-15 | 2019-04-12 | 易浦润（上海）生物技术有限公司 | A kind of in utero diaphragm apparatus for placing and its laying method |
| CN109758622A (en) * | 2018-04-19 | 2019-05-17 | 易浦润（上海）生物技术有限公司 | A kind of elastic membrane |
| CN110721393A (en) * | 2019-10-28 | 2020-01-24 | 易浦润（上海）生物技术有限公司 | Uterine stent and preparation method thereof |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| CN114246725A (en) * | 2021-12-16 | 2022-03-29 | 湖州市妇幼保健院 | Intrauterine device with anti-adhesion material |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017184669A1 (en) * | 2016-04-20 | 2017-10-26 | Duke University | Intrauterine adhesion barrier device and method of use |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171569A1 (en) * | 2000-04-25 | 2005-08-04 | Impres Medical, Inc. | Method and apparatus for creating intrauterine adhesions |
| US7252839B2 (en) * | 2002-09-18 | 2007-08-07 | Schering Oy | Delivery system and a manufacturing process of a delivery system |
| CN101229074A (en) * | 2008-02-27 | 2008-07-30 | 徐大宝 | Asherman's syndrom curing equipment |
| CN101278872A (en) * | 2007-04-05 | 2008-10-08 | 辽宁爱母医疗科技有限公司 | Nano memory alloy intrauterine device |
| CN201161050Y (en) * | 2008-02-27 | 2008-12-10 | 程春霞 | Instrument for treating uterine cavity synechiac |
| CN201182672Y (en) * | 2006-04-14 | 2009-01-21 | 辽宁爱母医疗科技有限公司 | Novel nano memory alloy intrauterine device |
| CN201618299U (en) * | 2009-12-23 | 2010-11-03 | 中国医学科学院生物医学工程研究所 | Intrauterine medicine slow-release device |
| CN201888869U (en) * | 2010-10-29 | 2011-07-06 | 湖南省计划生育研究所 | T-shaped intrauterine contraceptive device |
| CN202044643U (en) * | 2011-03-11 | 2011-11-23 | 东南大学 | Drug membrane-covered stent for preventing and curing intrauterine adhesion |
| CN102648868A (en) * | 2012-02-29 | 2012-08-29 | 徐大宝 | Intrauterine adhesion prevention and cure device |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060089658A1 (en) * | 2004-10-21 | 2006-04-27 | Harrington Douglas C | Method and apparatus for treating abnormal uterine bleeding |
-
2013
- 2013-01-06 CN CN201310003855.5A patent/CN103784244B/en active Active
- 2013-12-30 WO PCT/CN2013/001654 patent/WO2014106315A1/en active Application Filing
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171569A1 (en) * | 2000-04-25 | 2005-08-04 | Impres Medical, Inc. | Method and apparatus for creating intrauterine adhesions |
| US7252839B2 (en) * | 2002-09-18 | 2007-08-07 | Schering Oy | Delivery system and a manufacturing process of a delivery system |
| CN201182672Y (en) * | 2006-04-14 | 2009-01-21 | 辽宁爱母医疗科技有限公司 | Novel nano memory alloy intrauterine device |
| CN101278872A (en) * | 2007-04-05 | 2008-10-08 | 辽宁爱母医疗科技有限公司 | Nano memory alloy intrauterine device |
| CN101229074A (en) * | 2008-02-27 | 2008-07-30 | 徐大宝 | Asherman's syndrom curing equipment |
| CN201161050Y (en) * | 2008-02-27 | 2008-12-10 | 程春霞 | Instrument for treating uterine cavity synechiac |
| CN201618299U (en) * | 2009-12-23 | 2010-11-03 | 中国医学科学院生物医学工程研究所 | Intrauterine medicine slow-release device |
| CN201888869U (en) * | 2010-10-29 | 2011-07-06 | 湖南省计划生育研究所 | T-shaped intrauterine contraceptive device |
| CN202044643U (en) * | 2011-03-11 | 2011-11-23 | 东南大学 | Drug membrane-covered stent for preventing and curing intrauterine adhesion |
| CN102648868A (en) * | 2012-02-29 | 2012-08-29 | 徐大宝 | Intrauterine adhesion prevention and cure device |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078642A (en) * | 2014-05-14 | 2015-11-25 | 饶永 | Implant for uteruses |
| CN105078642B (en) * | 2014-05-14 | 2018-07-24 | 吴江永元生物科技有限公司 | A kind of uterus implant |
| CN106573133A (en) * | 2014-08-19 | 2017-04-19 | 加利福尼亚大学董事会 | Implants for localized drug delivery and methods of use thereof |
| CN105982779A (en) * | 2015-02-10 | 2016-10-05 | 刘雯倩 | Contraceptive ring |
| CN104998343A (en) * | 2015-07-24 | 2015-10-28 | 严聪颖 | Medicine-prefilled and sustained-release apparatus for uterus uses and implantation method |
| CN105903092A (en) * | 2016-06-23 | 2016-08-31 | 刘芸 | Uterus implant and implanting system for same |
| CN107951550A (en) * | 2017-12-14 | 2018-04-24 | 易浦润（上海）生物技术有限公司 | A kind of degradable inner membrane of uterine cavity implant system |
| CN113262332B (en) * | 2018-04-19 | 2022-06-24 | 易浦润（上海）生物技术有限公司 | Elastic film |
| CN109758622A (en) * | 2018-04-19 | 2019-05-17 | 易浦润（上海）生物技术有限公司 | A kind of elastic membrane |
| CN109758622B (en) * | 2018-04-19 | 2021-08-06 | 易浦润（上海）生物技术有限公司 | Elastic film |
| CN113262332A (en) * | 2018-04-19 | 2021-08-17 | 易浦润（上海）生物技术有限公司 | Elastic film |
| CN108852569A (en) * | 2018-05-21 | 2018-11-23 | 柏为（武汉）医疗科技股份有限公司 | A kind of degradable support diaphragm apparatus for preventing and treating Asherman's syndrom |
| CN109602535A (en) * | 2019-02-15 | 2019-04-12 | 易浦润（上海）生物技术有限公司 | A kind of in utero diaphragm apparatus for placing and its laying method |
| CN109602535B (en) * | 2019-02-15 | 2024-03-22 | 易浦润（上海）生物技术有限公司 | Intrauterine membrane placement device and placement method thereof |
| CN110721393A (en) * | 2019-10-28 | 2020-01-24 | 易浦润（上海）生物技术有限公司 | Uterine stent and preparation method thereof |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| CN114246725A (en) * | 2021-12-16 | 2022-03-29 | 湖州市妇幼保健院 | Intrauterine device with anti-adhesion material |
| CN114246725B (en) * | 2021-12-16 | 2024-01-12 | 湖州市妇幼保健院 | Intrauterine device with anti-adhesion material |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103784244B (en) | 2016-03-23 |
| WO2014106315A1 (en) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103784244B (en) | A kind of intrauterine implant | |
| CN105078642B (en) | A kind of uterus implant | |
| JP5951480B2 (en) | On-demand contraceptive methods | |
| CN104146948B (en) | Integral type pesseulum comprising progesterone with and preparation method thereof | |
| JP2001524124A (en) | Vaginal drug delivery device for administration of testosterone and testosterone precursor | |
| ES2561823T3 (en) | Contraception method once a month | |
| CN101626760A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| NO316707B1 (en) | Intravaginal drug delivery device, method of preparation thereof and use | |
| CN106573133A (en) | Implants for localized drug delivery and methods of use thereof | |
| CN107744417A (en) | One kind can post-operation adhesion preventing apparatus in degradable uterine cavity | |
| CN1652798A (en) | Continuous sulfatase inhibiting progestogen hormone replacement therapy | |
| CN103417272B (en) | A kind of medicine distribution type uterus support | |
| CN103637836A (en) | Intrauterine adhesion prevention and treatment device | |
| Rafiei et al. | Development of hormonal intravaginal rings: technology and challenges | |
| CN103301558B (en) | Inductive uterine slow release system | |
| Tejuja | Use of subcutaneous Silastic capsules for long-term steroid contraception | |
| CN109513097A (en) | A kind of two-tube balloon-stent for preventing and treating Asherman's syndrom | |
| CN202044643U (en) | Drug membrane-covered stent for preventing and curing intrauterine adhesion | |
| CN201618299U (en) | Intrauterine medicine slow-release device | |
| Pompei et al. | Morphometric evaluation of effects of two sex steroids on mammary gland of female rats | |
| Urbán-Morlán et al. | New developments in intrauterine drug delivery systems and devices | |
| CN203341802U (en) | Induction-type uterine cavity delay release system | |
| CN203539420U (en) | Medicine-distribution type uterus stent | |
| CN104203169B (en) | Comprising the pessary of the reagent of the release of meloxicam and the described active component of adjustment, it can be used as the contraceptive used continuously in women | |
| CN2525971Y (en) | Pessary of slow-released mifepristone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160112 Address after: 215200 south side of Yunlong Road West, Wujiang economic and Technological Development Zone, Suzhou, Jiangsu 215200 Applicant after: Wujiang Yongyuan Biotechnology Co., Ltd. Address before: 100021, Beijing, Chaoyang District, Jinsong agricultural light East 13 Building No. 1607 Applicant before: Rao Yong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |